Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (5324)	1/4/2002 10:59:49 AM
From: Biomaven	Respond to of 52153

quid, First let me correct myself - the merger was with Boehringer Mannheim not Ingelheim. It was consummated in 1997 with a purchase price of around $11 billion. However note that BM was more than its diagnostics division - it also had pharma sales of around a billion and a big orthopedic division (DePuy). The BM diagnostics seem to have been about half of the BM sales prior to the merger. It is pretty clear to me that the license is worth far more to Roche than to anyone else. Abbott already has a system and so they wouldn't be interested. Bayer is a possibility, but it would be very tough to successfully compete in this centralized testing market starting from virtually scratch. Peter